IRIS
NATOLI, Clara
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 12.006
EU - Europa 8.896
AS - Asia 6.856
SA - Sud America 887
Continente sconosciuto - Info sul continente non disponibili 867
AF - Africa 102
OC - Oceania 7
AN - Antartide 1
Totale 29.622
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 11.785
SG - Singapore 2.879
RU - Federazione Russa 2.707
CN - Cina 1.841
IT - Italia 1.067
IE - Irlanda 1.026
UA - Ucraina 914
SE - Svezia 792
FR - Francia 715
BR - Brasile 693
GB - Regno Unito 668
TR - Turchia 645
VN - Vietnam 622
DE - Germania 483
IN - India 281
FI - Finlandia 168
HK - Hong Kong 124
BD - Bangladesh 122
CA - Canada 99
AR - Argentina 64
AT - Austria 62
MX - Messico 62
PL - Polonia 62
BE - Belgio 52
JP - Giappone 52
IQ - Iraq 48
ES - Italia 40
NL - Olanda 35
CO - Colombia 31
ZA - Sudafrica 31
CZ - Repubblica Ceca 30
PK - Pakistan 28
SA - Arabia Saudita 23
KR - Corea 22
EC - Ecuador 21
PH - Filippine 20
VE - Venezuela 20
CL - Cile 19
EG - Egitto 19
ID - Indonesia 18
UZ - Uzbekistan 18
EU - Europa 17
JM - Giamaica 17
AE - Emirati Arabi Uniti 14
PY - Paraguay 13
AL - Albania 12
KE - Kenya 12
LT - Lituania 12
RO - Romania 12
JO - Giordania 11
MA - Marocco 11
PE - Perù 10
BO - Bolivia 9
IL - Israele 9
LB - Libano 9
TH - Thailandia 8
TN - Tunisia 8
AU - Australia 7
DZ - Algeria 7
IR - Iran 7
MY - Malesia 7
NP - Nepal 7
UY - Uruguay 7
AZ - Azerbaigian 6
CH - Svizzera 6
DO - Repubblica Dominicana 6
GT - Guatemala 6
HN - Honduras 6
TT - Trinidad e Tobago 6
GR - Grecia 5
OM - Oman 5
SN - Senegal 5
CR - Costa Rica 4
DK - Danimarca 4
ET - Etiopia 4
KW - Kuwait 4
NI - Nicaragua 4
PT - Portogallo 4
BG - Bulgaria 3
GE - Georgia 3
HR - Croazia 3
KG - Kirghizistan 3
MT - Malta 3
TW - Taiwan 3
AM - Armenia 2
BH - Bahrain 2
BS - Bahamas 2
CI - Costa d'Avorio 2
DM - Dominica 2
HU - Ungheria 2
KH - Cambogia 2
KZ - Kazakistan 2
MK - Macedonia 2
MM - Myanmar 2
QA - Qatar 2
XK - ???statistics.table.value.countryCode.XK??? 2
AF - Afghanistan, Repubblica islamica di 1
AO - Angola 1
AQ - Antartide 1
BA - Bosnia-Erzegovina 1
Totale 28.755
Salva come PNG Salva come JPEG
Città #
Singapore 2.187
Chandler 1.479
San Jose 1.277
Jacksonville 1.170
Dublin 1.016
Ashburn 763
Dallas 569
Beijing 488
Princeton 466
Los Angeles 446
Southend 414
Council Bluffs 382
Izmir 378
Nanjing 342
Wilmington 225
Santa Clara 223
Ho Chi Minh City 200
The Dalles 196
Dearborn 189
New York 181
Ann Arbor 177
Cambridge 176
Altamura 167
Boardman 149
Chieti 142
Nanchang 127
Hanoi 126
Buffalo 120
Hong Kong 111
Tongling 111
Munich 103
Houston 98
Woodbridge 93
Moscow 82
São Paulo 75
Redondo Beach 70
Dong Ket 68
Shenyang 63
Orem 61
Rome 61
Hebei 60
Chicago 54
Kunming 54
Tianjin 51
Brooklyn 49
Brussels 49
Tokyo 46
Warsaw 46
Vienna 45
Washington 45
Denver 40
Jiaxing 40
London 40
Norwalk 39
Phoenix 39
Milan 38
Atlanta 37
Montreal 37
Nuremberg 37
Columbus 36
Frankfurt am Main 33
Pescara 33
Stockholm 32
Boston 30
Da Nang 29
Hyderabad 29
Helsinki 28
Seattle 28
Chennai 26
Johannesburg 25
San Francisco 25
Mexico City 24
Changsha 23
Haiphong 23
Poplar 23
Brno 22
Falls Church 22
Hangzhou 22
Mumbai 22
Manchester 21
Belo Horizonte 20
Hefei 20
Rio de Janeiro 20
Kocaeli 19
Seoul 19
Toronto 19
Amsterdam 18
Baghdad 18
San Mateo 17
Lanzhou 16
Shanghai 16
St Louis 16
Tashkent 16
Turku 16
Düsseldorf 15
Naples 15
Auburn Hills 14
Augusta 14
Tappahannock 14
Cairo 13
Totale 16.508
Salva come PNG Salva come JPEG
Nome #
"Triple positive" early breast cancer: An observational multicenter retrospective analysis of outcome 927
A Real-World Multicentre Retrospective Study of Paclitaxel-Bevacizumab and Maintenance Therapy as First-Line for HER2-Negative Metastatic Breast Cancer 903
Alpelisib for PIK3CA-mutated, hormone receptor-positive advanced breast cancer 832
Adjuvant anastrozole versus exemestane versus letrozole, upfront or after 2 years of tamoxifen, in endocrine-sensitive breast cancer (FATA-GIM3): a randomised, phase 3 trial 363
45: L’UTILIZZO DELL’IMMUNOTERAPIA PER IL TRATTAMENTO DELL’ADENOCARCINOMA POLMONARE IN II LINEA: NIVOLUMAB VS PEMBROLIZUMAB 341
90K (Mac-2 BP) in human milk 242
A phase I study of recombinant interferon-alpha administered as a seven-day continuous venous infusion at circadian-rhythm modulated rate in patients with cancer. 212
Circulating Cancer Stem Cell-Derived Extracellular Vesicles as a Novel Biomarker for Clinical Outcome Evaluation 198
Comparison between CaGene 5.1 and 6.0 for BRCA1/2 mutation prediction: a retrospective study of 150 BRCA1/2 genetic tests in 517 families with breast/ovarian cancer 190
Impact of BMI on clinical outcome in advanced cancer patients treated with anti‑PD‑1 Immune checkpoint inhibitors: a preliminary analysis 189
90K (Mac-2 BP) and galectins in tumor progression and metastasis. 188
A multidisciplinary group for prostate cancer management: A single institution experience 186
Breast cancer "tailored follow-up" in Italian oncology units: A web-based survey 184
A retrospective multicentric observational study of trastuzumab emtansine in HER2 positive metastatic breast cancer: a real-world experience 176
A phase II study of dose-dense epirubicin plus cyclophosphamide followed by docetaxel plus capecitabine and pegfilgrastim support as preoperative therapy for patients with stage II, IIIA breast cancer. 172
90K (MAC-2 BP) gene expression in breast cancer and evidence for the production of 90K by peripheral-blood mononuclear cells 170
Combination of peripheral neutrophil-to-lymphocyte ratio and platelet-to-lymphocyte ratio is predictive of pathological complete response after neoadjuvant chemotherapy in breast cancer patients 170
90K protein in HIV infection: evidence of its release from peripheral blood mononuclear cells 169
Neoadjuvant chemotherapy in triple-negative breast cancer: A multicentric retrospective observational study in real-life setting 169
Expression of glycoprotein 90K in human malignant pleural mesothelioma: correlation with patients survival. 166
The 90K tumor associated antigen and clinical progression in human immunodeficiency virus infection 164
A phase I study of 5-day continuous venous infusion of carboplatin (CBDCA) at circadian rhythm-modulated rate 164
Body Mass Index and Treatment Outcomes in Metastatic Breast Cancer Patients Treated With Eribulin 164
Gli analoghi sintetici delle glicoamine come potenziali nuovi farmaci nella prevenzione delle metastasi 161
ABIRATERONE ACETATE FOR TREATMENT OF METASTATIC CASTRATION-RESISTANT PROSTATE CANCER IN CHEMOTHERAPY-NAIVE PATIENTS: AN ITALIAN MULTICENTER 'REAL-LIFE' 1-YEAR STUDY 160
A Case of Stage I Vulvar Squamous Cell Carcinoma with Early Relapse and Rapid Disease Progression 160
Abiraterone Acetate for Treatment of Metastatic Castration-resistant Prostate Cancer in Chemotherapy-naive Patients: An Italian Analysis of Patients' Satisfaction 159
Effects of repurposed drug candidates nitroxoline and nelfinavir as single agents or in combination with erlotinib in pancreatic cancer cells 158
A multicenter study of body mass index in cancer patients treated with anti-PD-1/PD-L1 immune checkpoint inhibitors: when overweight becomes favorable 158
Epidermal Growth Factor Immunotherapy: Exploring the Effects of NB-UVB Exposure 158
90K (Mac-2 BP) predicts CD4 decline in human immunodeficiency virus-infected patients with CD4 counts above 200 x 10^6 cells/L 157
Trastuzumab Emtansine (T-DM1) in Patients (pts) With Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Metastatic Breast Cancer (MBC): results From a Multicenter Retrospective Analysis 157
A phase II study of cisplatin, epirubicin, vindesine chemotherapy and lonidamine in advanced nonsmall cell lung cancer 156
90k is a serum marker of poor-prognosis in non-hodgkins-lymphoma patients. 154
A novel serum test using interferon for early detection of tumor reccurrence in cancer patients after radical surgery. 153
Elevated serum levels of 90K/MAC-2BP predict unresponsiveness to alfa-interferon therapy in chronic HCV hepatitis patients 150
Body mass index modifies the relationship between γ-H2AX, a DNA damage biomarker, and pathological complete response in triple-negative breast cancer 150
High expression of 90K (Mac-2 BP) is associated with poor survival in node-negative breast cancer patients not receiving adjuvant systemic therapies 149
Effect of Gender on the Outcome of Patients Receiving Immune Checkpoint Inhibitors for Advanced Cancer: A Systematic Review and Meta-Analysis of Phase III Randomized Clinical Trials 149
A PHASE II STUDY OF NEOADJUVANT CHEMOTHERAPY WITH CISTAPLIN, EPIRUBICIN AND VP – 16 FOR STAGE III UNRESECTABLE NON-SMALL CELL LUNG CANCER 148
Purification and characterization of a 90 kDa protein releasedfrom human tumors and tumor cell lines 148
An Epigenetic Approach to Pancreatic Cancer Treatment: the Prospective Role of Histone Deacetylase Inhibitors 147
New Targets for Therapy in Pancreatic Cancer 146
A phase I study of 5-day continuous venous infusion of carboplatin (CBDCA) at circadian rhythm-modulated rate 145
Long-term outcome of neoadjuvant systemic therapy for locally advanced breast cancer in routine clinical practice. 145
A 90-kDa protein serum marker for the prediction of progression to AIDS in a cohort of HIV-1+ homosexual men. 143
Glicomimetici quali potenziali nuovi farmaci per la prevenzione delle metastasi. 142
Extraordinary and prolonged erlotinib-induced clinical response in a patient with EGFR wild-type squamous lung cancer in third-line therapy: A case report 142
Treatment of metastatic colorectal cancer patients 75 years old in clinical practice: A multicenter analysis 141
Fulvestrant (FUL) 500 milligrams as endocrine therapy (ET) for hormone sensitive advanced breast cancer patients (pts). The Ful500 prospective observational trial 140
Fasting glucose and body mass index as predictors of activity in breast cancer patients treated with everolimus-exemestane: The EverExt study 139
Palbociclib plus endocrine therapy in HER2 negative, hormonal receptor-positive, advanced breast cancer: A real-world experience 139
Inhibition of tumor growth and angiogenesis by SP-2, an anti-LGALS3BP antibody 137
Anthropometric, clinical and molecular determinants of treatment outcomes in postmenopausal, hormone receptor positive metastatic breast cancer patients treated with fulvestrant: Results from a real word setting 137
BIOLOGICAL INDICATORS OF PROGNOSIS IN HUMAN CANCER: AN EMERGING ROLE FOR LECTIN GALACTOSIDE-BINDING SOLUBLE 3-BINDING PROTEIN (LGALS3BP) 136
Biochemical and pharmacological characterization of the cyclooxygenase activity of human blood prostaglandin endoperoxide synthases 135
Chemotherapy preoperative for the management of breast cancer locally advanced 135
Long-term outcome of neoadjuvant endocrine therapy with aromatase inhibitors in elderly women with hormone receptor-positive breast cancer 134
Fulvestrant 500 milligrams as endocrine therapy for endocrine sensitive advanced breast cancer patients in the real world: the Ful500 prospective observational trial. 133
Influenza vaccine indication during anticancer therapy with immune-checkpoint inhibitors: A transversal challenge for patient’s counselling – preliminary analysis of the INVIDIa study 133
Safety and efficacy of abiraterone acetate in chemotherapy-naive patients with metastatic castration-resistant prostate cancer: an Italian multicenter "real life" study 133
Changes of topoisomerase IIalpha expression in breast tumors after neoadjuvant chemotherapy predicts relapse-free survival 132
90K protein: a new predictor marker of disease progression in human immunodeficiency virus infection. 132
Inhibition of tumor growth and angiogenesis by SP-2, an anti-lectin, galactoside-binding soluble 3 binding protein (LGALS3BP) antibody. 132
Expression of tumor associated 90K-antigen in human breast cancer: no correlation with prognosis and response to first-line therapy with tamoxifen 131
Elevated serum levels of a 90,000 daltons tumor-associated antigen in cancer and in infection by human immunodeficiency virus (HIV). 131
Adhesion to 90K (Mac-2 BP) as a mechanism for lymphoma drug resistance in vivo. 130
Distinct HR expression patterns significantly affect the clinical behavior of metastatic HER2+ breast cancer and degree of benefit from novel anti-HER2 agents in the real world setting 130
A Flow cytometric study of early gastric cancer 129
TGF-β-1 increases 90K tumor associated antigen gene expression by increasing upstream regulatory factor binding to the minimal promoter. 128
Chronomodulated infusion of cisplatin, 5-fluorouracil and folinic acid: lack of activity in advanced colorectal cancer. 128
Sunitinib malate (SU-11248) alone or in combination with low-dose docetaxel inhibits the growth of DU-145 prostate cancer xenografts. 128
Outcomes of HER2-positive early breast cancer patients in the pre-trastuzumab and trastuzumab eras: a real-world multicenter observational analysis. The RETROHER study 128
Adherence to hormonal deprivation therapy in prostate cancer in clinical practice: a retrospective, single-centre study 128
A multicenter REtrospective observational study of first-line treatment with PERtuzumab, trastuzumab and taxanes for advanced HER2 positive breast cancer patients. RePer Study 128
Do cut-off values of lymph node ratio and presence of perineural invasion affect survival in breast cancer patients with pathologic N3a lymph node stage? Reply to Kadri Altundag 127
Family history of cancer as surrogate predictor for immunotherapy with anti-PD-1/PD-L1 immune checkpoint inhibitors: The FAMI-L1 study 127
Weight loss and body mass index in advanced gastric cancer patients treated with second-line ramucirumab: a real-life multicentre study 126
Long-term outcome of breast cancer patients with pathologic N3a lymph node stage 125
Predictive factors of response to neoadjuvant chemotherapy (NAT) in triple negative breast (TNBC) cancer patients: A restrospective multicenter observational study. 125
Darolutamide in Nonmetastatic, Castration-Resistant Prostate Cancer 125
Expression of the 90K tumor-associated protein in benign and malignant melanocytic lesions. 124
Interleukin-30 Promotes Breast Cancer Growth and Progression 124
Principali effetti collaterali delle terapie mediche 124
Corrigendum to "Circulating Cancer Stem Cell-Derived Extracellular Vesicles as a Novel Biomarker for Clinical Outcome Evaluation" 124
Surgical treatment of adrenal metastases from non small cell lung cancer 123
DNA ploidy and S-phase fraction in pulmonary carcinoids. 123
Tumor-derived microvesicles: The metastasomes. 123
Palliative radiotherapy in advanced cancer patients treated with immune-checkpoint inhibitors: The PRACTICE study 123
Prognostic value of 90K protein in HIV infection 122
Tyrosine kinase inhibitors 122
Identification of Subgroups of Early Breast Cancer Patients at High Risk of Nonadherence to Adjuvant Hormone Therapy: Results of an Italian Survey 122
Tgf-β1 transcriptionally promotes 90K expression: possible implications for cancer progression 121
Prognostic value of a novel circulating serum 90K antigen in breast cancer 120
Unknown primary tumors 120
Multicentric retrospective analysis of platinum-pemetrexed regimens as first-line therapy in non-squamous non-small cell lung cancer patients: A “snapshot” from clinical practice 120
Alectinib induced regression of renal and hepatic cysts caused by crizotinib 120
Topographic expression of the Hippo transducers TAZ and YAP in triple-negative breast cancer treated with neoadjuvant chemotherapy 119
Safety analysis, association with response and previous treatments of everolimus and exemestane in 181 metastatic breast cancer patients: A multicenter Italian experience 119
Bone marrow micrometastases detected by a monoclonal antibody in patients with breast cancer. 118
Totale 17.087
Salva come PNG Salva come JPEG
Categoria #
all - tutte 108.236
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 108.236
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2021/20221.036 0 0 8 193 114 26 23 69 78 28 131 366
2022/20233.858 310 474 269 470 390 717 200 328 445 37 133 85
2023/20241.589 130 55 119 47 126 552 286 49 25 49 16 135
2024/20253.673 202 692 532 115 86 173 137 218 355 188 418 557
2025/202610.600 674 378 979 925 838 588 1.529 495 2.812 716 449 217
2026/20271.118 350 614 154 0 0 0 0 0 0 0 0 0
Totale 29.622